glp 1 for heart disease GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies SGLTi and GLP-1 in HF
Description
doi: 10.4103/2230-8210.111625
Compare outcome analytic function was utilized to determine risk of ESRD within 5 years among both groups
It is significantly boosting the risk of diabetes development
Supply shortages of Wegovy and others may impact successful treatment
3 : Use EHR and claims data to identify overdose survivors and measure long-term outcomes across different treatment approaches
Lancet Diabetes Endocrinol 4(6):537547
